Mouse GITR/TNFRSF18 Alexa Fluor® 488-conjugated Antibody
R&D Systems, part of Bio-Techne | Catalog # FAB5241G
Key Product Details
Species Reactivity
Validated:
Cited:
Applications
Validated:
Cited:
Label
Antibody Source
Product Specifications
Immunogen
Met1-His153
Accession # O35714
Specificity
Clonality
Host
Isotype
Applications for Mouse GITR/TNFRSF18 Alexa Fluor® 488-conjugated Antibody
Flow Cytometry
Sample: Mouse splenocytes
Formulation, Preparation, and Storage
Purification
Formulation
Shipping
Stability & Storage
Background: GITR/TNFRSF18
GITR (glucocorticoid-induced tumor necrosis factor receptor; also named AITR) is a member of the co‑stimulatory subset of the TNF receptor superfamily (1, 2). In mouse, the GITR gene is composed of five exons and encodes multiple length isoforms that arise from alternate splicing. The “standard”, or first reported isoform is a type I transmembrane protein, 228 amino acids (aa) in length that contains a 19 aa signal sequence, a 134 aa extracellular region, a 21 aa transmembrane segment, and a 54 aa cytoplasmic domain. The extracellular region contains four potential N-linked glycosylation sites plus three cysteine-rich pseudorepeats of about 40 aa each (3, 4). The extracellular regions of mouse and human are 57% aa identical. The cytoplasmic domain has a P-x-Q/E-E motif that is known to associate with TRAF2. This is a common characteristic of TNFRSF members with co‑stimulatory functions (4). Three other mouse GITR isoforms (B, C and D) have been reported (5). All share the same N-terminal 101 of 134 aa in the extracellular region (including pseudorepeats #1, #2 and one-half of #3). Isoform D diverges at aa #101 and continues for another 12 aa for a total length of 113 aa. This is a naturally-occurring soluble form. Isoforms B and C show splicing in their cytoplasmic tails that creates cytoplasmic domains of 118 aa and 46 aa, respectively. In both the B and C isoforms, the TRAF2 binding site is spliced out, with a p56lck binding site inserted in isoform B (4). Given its membership in the TNFRSF, it likely functions as a trimer on the cell surface (2). GITR is predominantly expressed on CD4+CD25+ regulatory T cells (Treg) and naïve CD8+ and CD4+ CD25- T cells, where its expression is up-regulated after antigen-driven activation. GITR activation provides co‑stimulatory signals for activated CD4+ CD25- T cells to enhance cell proliferation and augment cytokine production (IL-2, IL-4, IFN-gamma). On CD4+ CD25+ Treg cells, GITR activation provides co‑stimulatory signals to induce proliferation, setting Treg cells in an active/hyperproliferactive state (6‑8).
References
- Kwon, B. et al. (2003) Exp. Mol. Med. 35:8.
- Croft, M. (2003) Nat. Rev. Immunol. 3:609.
- Nocentini, G. et al. (1997) Proc. Natl. Acad. Sci. USA 94:6216.
- Nocentini, G. et al. (2000) DNA Cell Biol. 19:205.
- Nocentini, G. et al. (2000) Cell Death Differ. 7:408.
- Tone, M. et al. (2003) Proc. Natl. Acad. Sci. USA 100:15059.
- Ji, H. et al. (2004) J. Immunol. 172:5823.
- Stephens, G.L. et al. (2004) 173:5008.
Long Name
Alternate Names
Gene Symbol
UniProt
Additional GITR/TNFRSF18 Products
Product Documents for Mouse GITR/TNFRSF18 Alexa Fluor® 488-conjugated Antibody
Product Specific Notices for Mouse GITR/TNFRSF18 Alexa Fluor® 488-conjugated Antibody
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
For research use only